Selecting the most suitable dosage form is a critical strategy for optimizing physicochemical properties such as chemical and physical stability, solubility, dissolution rate, and bioavailability.
Our focus is on combining the right dose form with the optimal formulation to achieve targeted release and exposure of medications in the blood and organs, with a focus on oral pharmaceutical drug delivery.
Our advanced drug delivery systems can address safety and efficacy limitations observed during clinical development of new molecular entities by improving their pharmacokinetic and pharmacodynamic profiles.
They can also offer drug developers new strategies for surviving patent cliffs by extending market exclusivity when the novel dose form addresses bona fide patient needs. For example, improved delivery systems can improve medication adherence and the patient experience by reducing dose frequency, side effects and invasiveness.
through greater water solubility, enhanced permeability and retention in target tissue.
allow for controlled time release of actives.
during manufacturing and throughout shelf life
with effective symptom relief, improved taste masking, and overall ease of use.
25mg and 50mg sildenafil oral dissolvable film for the treatment of erectile dysfunction.
We have completed our pre-IND meeting with the FDA, confirming a 505(b)(2) regulatory path.
We are developing several cannabinoid products with optimized pharmacokinetic profiles using microCURE and CUREfilm technology.